AbbVie Inc. (ABBV) operating KPIs
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)
Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%
AbbVie acquired IPR&D and Milestones Unfavorable Impact to Diluted EPS ($/sh) ($)
Form 8-K Earnings Release
Latest, FY2025
2.76
Period ended Dec 31, 2025
Change on a year earlier
+81.6%
1.52 in FY2024
History
5 years
Since FY2021
Sources
4
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Acquired IPR&D and Milestones Unfavorable Impact to Diluted EPS ($/sh) ($) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2.76 | +81.6% | Form 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗ |
| FY2024 | Dec 31, 2024 | 1.52 | +261.9% | Form 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗ |
| FY2023 | Dec 31, 2023 | 0.42 | +7.7% | Form 8-K (abbv-20241231xexhibit991.htm, filed 2025-01-31) ↗ |
| FY2022 | Dec 31, 2022 | 0.39 | -56.7% | Form 8-K (abbv-20231231xexhibit991.htm, filed 2024-02-02) ↗ |
| FY2021 | Dec 31, 2021 | 0.90 | – | Form 8-K (abbv-20221231xexhibit991.htm, filed 2023-02-09) ↗ |
Cite this data
StockData. (2026). AbbVie Acquired IPR&D and Milestones Unfavorable Impact to Diluted EPS ($/sh) ($), annual FY2021–FY2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/iprd_eps_impact
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.